NCT00450827View on ClinicalTrials.gov

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

bevacizumab

BIOLOGICAL

filgrastim

PROCEDURE

autologous hematopoietic stem cell transplantation

RADIATION

iodine I 131 monoclonal antibody 3F8

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00450827 - Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | Biotech Hunter | Biotech Hunter